Chemours CO 10-Q quarterly reports

The Chemours Company's Q2 2026 filing shows flat net sales, a net loss, and increased SG&A expenses, partially offset by a substantial gain from land sales.

Chemours reported a net loss of $29 million for Q1 2026, impacted by operational disruptions and ongoing legal costs.

Chemours reported a net loss of $325 million for the first nine months of 2025, driven by significant PFAS litigation settlements and operational challenges in its Titanium Technologies and Advanced Performance Materials segments.

The Chemours Company reported a significant net loss for the second quarter and first half of 2025, primarily driven by a substantial settlement agreement with the State of New Jersey related to PFAS liabilities.

Chemours reports relatively flat net sales but a net loss for Q1 2025, impacted by restructuring charges and revisions to prior period financial statements.

Chemours' Q3 2024 results show a net loss, impacted by a goodwill impairment charge and restructuring costs, despite a slight increase in net sales.

Chemours' Q2 2024 results show a return to profitability, but are impacted by ongoing internal reviews and market challenges.

Chemours' first quarter results for 2024 show a decrease in net sales and earnings, impacted by lower volumes and prices, and costs associated with an internal review.